GlassScriptPhysician profile
Kyle L Garner
NPI 1619935384
$9,166.03
in general payments reported to CMS, 2019-2025
41 companies · $876 in 2025
The $876 reported for 2025 was more than what 90% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $180 · 2021: $42.52 · 2022: $333 · 2023: $563 · 2024: $6,678 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $1,384 · Travel and Lodging: $694 · Education: $39.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $1,383.56 |
| Travel and Lodging | $693.79 |
| Education | $39.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Distalmotion US | $6,375.42 | 2024 | Dexter L6 Robot |
| Coloplast Corp | $627.08 | 2025 | |
| Astellas Pharma US INC | $350.83 | 2022-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $165.46 | 2019-2025 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Bayer Healthcare Pharmaceuticals INC. | $131.33 | 2019-2025 | |
| Pfizer INC. | $112.43 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $89.20 | 2019 | |
| Myriad Women'S Health, INC. | $84.20 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $83.64 | 2023-2025 | Myfembree |
| Amag Pharmaceuticals, INC. | $81.05 | 2019-2020 | |
| Dysis Medical, INC. | $75.91 | 2020 | |
| Abbvie INC. | $71.25 | 2019-2023 | |
| Millicent US INC | $64.39 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Smith+Nephew, INC. | $62.79 | 2019-2025 | Pico 14 |
| Merck Sharp & Dohme LLC | $59.93 | 2019-2023 | Gardasil 9 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $55.65 | 2022 | |
| Avion Pharmaceuticals | $51.80 | 2020-2023 | Balcoltra |
| Therapeuticsmd, INC. | $50.83 | 2019 | |
| Mayne Pharma Commercial LLC | $50.27 | 2023-2024 | |
| Coopersurgical, INC. | $47.84 | 2022-2024 | Summit Doppler |
| Evofem Biosciences, INC. | $45.94 | 2022 | |
| Baxter Healthcare | $38.35 | 2022 | |
| Mylan Pharmaceuticals INC. | $35.81 | 2019 | |
| Exeltis, USA INC. | $34.77 | 2020-2023 | Slynd |
| Cepheid | $32.72 | 2025 | |
| Gynesonics, INC. | $28.55 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Scynexis, INC. | $27.04 | 2022 | |
| Minerva Surgical, INC | $24.49 | 2022 | |
| Kci USA, INC. | $22.47 | 2019 | |
| Medtronic, INC. | $22.30 | 2025 | Truclear |
| Shield Therapeutics INC | $20.77 | 2024 | |
| Duchesnay USA Incorporated | $20.42 | 2019 | |
| Mimedx Group, INC. | $20.21 | 2024 | |
| Allergan, INC. | $17.04 | 2019 | |
| Amgen INC. | $16.53 | 2019 | |
| Exact Sciences Corporation | $14.70 | 2023 | Cologuard Collection Kit |
| Medicem INC. | $13.65 | 2022 | |
| Lupin INC. | $13.35 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.28 | 2019 | |
| Organon LLC | $12.34 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.